RGT 100

Drug Profile

RGT 100

Alternative Names: ImOl 100; RGT100; RGT100-PEI

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigontec
  • Class Antineoplastics; Gene therapies; Oligonucleotides; RNA
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 27 Oct 2017 Rigontec has been acquired by Merck & Co
  • 06 Sep 2017 Rigontec plans clinical trials for Solid tumours (Monotherapy, Combination therapy)
  • 03 Jan 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Recurrent) in United Kingdom, Germany after January 2017 (Intratumoural) (NCT03065023) (EudraCT2016-003028-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top